Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Терапия лимфомы Ходжкина в России в период пандемии COVID-19. Резолюция
________________________________________________
Poddubnaya I.V. et al. Therapy of Hodgkin lymphoma in Russia during the COVID-19 pandemic. Journal of Modern Oncology. 2020; 22 (2): 52–55. DOI: 10.26442/18151434.2020.2.200206
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Цель. Изменение и адаптация текущих подходов к лечению в сложившейся эпидемиологической обстановке.
Результаты. Определены основные аспекты влияния пандемии COVID-19 на лечение пациентов с кЛХ; выявлены ключевые проблемы при проведении лечения кЛХ во время пандемии COVID-19 и разработаны мероприятия, направленные на снижение риска для пациентов. Адаптированы подходы к 1-й линии терапии кЛХ; терапии рецидивирующей/рефрактерной кЛХ, проведению аллогенной и аутологичной трансплантации гемопоэтических стволовых клеток на период пандемии COVID-19.
Ключевые слова: лимфома Ходжкина, COVID-19, таргетная терапия, брентуксимаб ведотин.
________________________________________________
Relevance. COVID-19 pandemic currently has a significant negative impact on the treatment of patients with oncological pathology, including patients with classic Hodgkin lymphoma. Generalized data on publications on the impact of concomitant pathology on the severity of infection show a significant increase in the risk of death from infection in male patients, aged >60 years, with the presence of ≥3 concomitant diseases, among which particularly negative role is played by diseases of the cardiovascular system, diabetes, oncology, chronic lung disease, immunodeficiency conditions. Particularly dangerous is the development of COVID-19 infection in an interval of less than 14 days from the course of antitumor therapy. At the same time, patients with Hodgkin lymphoma require immediate treatment, often associated with toxic, immunosuppressive therapy, frequent visits to the clinic, hospitalizations. International communities have not yet developed clear guidelines for the management of patients with Hodgkin's lymphoma. Taking into account the understanding that the circulation of coronoviral infection will continue in the population, the Advisory board on the Problems of Hodgkin Lymphoma Therapy in the COVID-19 Pandemic is highly relevant.
Aim. To change and adapt current treatment approaches in the current epidemiological environment.
Results. The main directions of the impact of the COVID-19 pandemic on the treatment of patients with cancer pathology, including patients with classical Hodgkin lymphoma, were determined, key problems in the treatment of LC during the COVID-19 pandemic were identified, and measures aimed at reducing the risk for patients were developed. Existing approaches to first-line, relapse/refracturing cHL therapy, including salvage therapy, and auto/allo SCT during the COVID-19 pandemic, have been adapted.
Key words: Hodgkin lymphoma, COVID-19.
2. https://www.cdc.gov/coronavirus/2019-ncov/
3. https://www.hematology.org/covid-19/covid-19-and-hodgkin-lymphoma
4. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/haematologica...
5. Liang W et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology 2020; 21 (3): 335–7. DOI: 10.1016/S1470-2045(20)30096-6
6. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020; 32 3(18): 1775–6. DOI: 10.1001/jama.2020.4683
7. Lambertini M, Toss A, Passaro A et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’perspective. ESMO Open 2020; 5: e000759. DOI: 10.1136/esmoopen-2020-000759
8. Hanna TP, Evans GA, Booth CM et al. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020; 17: 268–70.
9. Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy 2020; 0(0): imt-2020-0067. DOI: 10.2217/imt-2020-0067
10. https://clinicaltrials.gov/ct2/show/NCT03474133?term=basalt&draw=2&rank=1
________________________________________________
1. https://www.worldometers.info/coronavirus/
2. https://www.cdc.gov/coronavirus/2019-ncov/
3. https://www.hematology.org/covid-19/covid-19-and-hodgkin-lymphoma
4. https://www.esmo.org/guidelines/cancer-patient-management-during-the-covid-19-pandemic/haematologica...
5. Liang W et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncology 2020; 21 (3): 335–7. DOI: 10.1016/S1470-2045(20)30096-6
6. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 2020; 32 3(18): 1775–6. DOI: 10.1001/jama.2020.4683
7. Lambertini M, Toss A, Passaro A et al. Cancer care during the spread of coronavirus disease 2019 (COVID-19) in Italy: young oncologists’perspective. ESMO Open 2020; 5: e000759. DOI: 10.1136/esmoopen-2020-000759
8. Hanna TP, Evans GA, Booth CM et al. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat Rev Clin Oncol 2020; 17: 268–70.
9. Bersanelli M. Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy 2020; 0(0): imt-2020-0067. DOI: 10.2217/imt-2020-0067
10. https://clinicaltrials.gov/ct2/show/NCT03474133?term=basalt&draw=2&rank=1